Your browser is no longer supported. Please, upgrade your browser.
ONCY Oncolytics Biotech Inc. daily Stock Chart
Oncolytics Biotech Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own1.80% Shs Outstand39.60M Perf Week-17.09%
Market Cap70.27M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float38.76M Perf Month-16.67%
Income-22.10M PEG- EPS next Q-0.11 Inst Own2.50% Short Float5.00% Perf Quarter-18.32%
Sales- P/S- EPS this Y-40.70% Inst Trans74.91% Short Ratio2.14 Perf Half Y-35.55%
Book/sh0.46 P/B3.59 EPS next Y- ROA-111.70% Target Price- Perf Year184.48%
Cash/sh0.53 P/C3.12 EPS next 5Y- ROE-231.30% 52W Range0.35 - 6.02 Perf YTD-65.34%
Dividend- P/FCF- EPS past 5Y5.80% ROI- 52W High-73.82% Beta2.53
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low348.95% ATR0.13
Employees23 Current Ratio8.80 Sales Q/Q- Oper. Margin- RSI (14)28.62 Volatility7.03% 6.55%
OptionableNo Debt/Eq0.01 EPS Q/Q33.80% Profit Margin- Rel Volume1.29 Prev Close1.65
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume905.96K Price1.58
Recom- SMA20-20.92% SMA50-20.47% SMA200-20.56% Volume151,958 Change-4.50%
Aug-10-20 07:00AM  
Aug-04-20 04:01PM  
Jun-25-20 07:00AM  
Jun-23-20 07:00AM  
Jun-15-20 08:15PM  
Jun-04-20 07:00AM  
May-29-20 07:00AM  
May-26-20 07:00AM  
May-18-20 02:47PM  
May-14-20 07:00AM  
May-13-20 07:00AM  
May-12-20 10:38AM  
May-08-20 07:00AM  
May-05-20 03:11PM  
May-04-20 07:00AM  
Apr-30-20 07:00AM  
Apr-17-20 05:13PM  
Apr-15-20 12:51PM  
Apr-02-20 07:00AM  
Mar-24-20 07:00AM  
Mar-05-20 04:00PM  
Feb-28-20 10:15AM  
Feb-11-20 09:22AM  
Jan-27-20 07:00AM  
Jan-23-20 09:51AM  
Jan-22-20 08:12AM  
Jan-21-20 02:40PM  
Jan-13-20 07:00AM  
Jan-09-20 07:00AM  
Jan-06-20 07:36AM  
Dec-12-19 07:00AM  
Dec-09-19 07:00AM  
Dec-06-19 07:00AM  
Dec-03-19 07:00AM  
Nov-25-19 10:03AM  
Nov-12-19 04:00PM  
Nov-08-19 07:00AM  
Nov-07-19 07:00AM  
Nov-06-19 07:00AM  
Nov-05-19 07:00AM  
Oct-31-19 07:00AM  
Oct-22-19 07:00AM  
Oct-17-19 07:00AM  
Oct-15-19 07:00AM  
Oct-01-19 07:00AM  
Sep-30-19 07:00AM  
Sep-25-19 07:00AM  
Sep-23-19 07:00AM  
Sep-20-19 07:00PM  
Sep-17-19 07:00AM  
Sep-05-19 06:00PM  
Sep-04-19 07:00AM  
Aug-16-19 08:55AM  
Aug-15-19 07:45AM  
Aug-14-19 02:30PM  
Aug-13-19 04:15PM  
Jul-23-19 07:00AM  
Jun-05-19 07:00AM  
May-29-19 07:00AM  
May-16-19 07:00AM  
May-03-19 07:00AM  
Apr-25-19 07:00AM  
Apr-23-19 07:00AM  
Apr-08-19 07:00AM  
Apr-04-19 07:00AM  
Apr-03-19 07:00AM  
Apr-02-19 07:00AM  
Mar-28-19 07:00AM  
Mar-08-19 07:00AM  
Mar-01-19 07:00AM  
Feb-28-19 04:31PM  
Feb-27-19 04:55PM  
Feb-11-19 07:00AM  
Feb-04-19 07:00AM  
Dec-12-18 07:00AM  
Dec-03-18 07:00AM  
Nov-29-18 07:00AM  
Nov-27-18 07:32AM  
Nov-26-18 08:00AM  
Nov-13-18 07:00AM  
Nov-12-18 07:00AM  
Nov-09-18 07:00AM  
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.